Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. P. Meert, T. Berghmans, C. Mascaux, M. Paesmans, I. CsToth, L. Willems, N. Leclercq, G. Anthoine, J. P. Sculier (Brussels, Gembloux, Belgium). Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue. Eur Respir J 2010; 36: Suppl. 54, 1945

Member's Comments

No comment yet.

Related content which might interest you: The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Could 18F-FDG PET repeated within cycle 1 predicts objective response to chemotherapy in advanced non-small cell lung cancer (NSCLC)? A pilot study results Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Staging with FDG-PET/CT influences stage-specific survival in non small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Imaging in oncology and infectious diseases Year: 2011 Reflex testing  is crucial for treatment decisions in advanced non small cell lung cancer (NSCLC) Source: International Congress 2017 – Chinese Programme 2017 Year: 2017 Compassionate-use gefitinib in non–small cell lung cancer (NSCLC): results from a US expanded access program (EAP) Source: Eur Respir J 2004; 24: Suppl. 48, 231s Year: 2004 Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008 The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed (Pem) for advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010